Literature DB >> 12373481

Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.

Paul Pollack1, Jessie R Groothuis.   

Abstract

Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by respiratory syncytial virus (RSV). RSV causes significant morbidity and mortality in young children worldwide and is particularly severe in pre-term infants, children with cardiopulmonary disease, and the immunosuppressed population. The first such genetically engineered agent to be used effectively against a human infectious disease, palivizumab significantly reduces the number of hospitalizations caused by RSV in high-risk infants. This article reviews the preclinical development and clinical experience of palivizumab.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12373481     DOI： 10.1007/s10156-002-0178-6

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN： 1341-321X            Impact factor:   2.211


  16 in total

1.  Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Kimberly A Bishop; Vidita Choudhry; Bruce A Mungall; Yan-Ru Feng; Anil Choudhary; Mei-Yun Zhang; Yang Feng; Lin-Fa Wang; Xiaodong Xiao; Bryan T Eaton; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 2.  Bispecific antibodies for viral immunotherapy.

Authors:  Elisabeth K Nyakatura; Alexandra Y Soare; Jonathan R Lai
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

3.  Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus.

Authors:  Nicole Pribut; Thomas M Kaiser; Robert J Wilson; Edgars Jecs; Zackery W Dentmon; Stephen C Pelly; Savita Sharma; Perry W Bartsch; Pieter B Burger; Soyon S Hwang; Thalia Le; Julien Sourimant; Jeong-Joong Yoon; Richard K Plemper; Dennis C Liotta
Journal:  ACS Infect Dis       Date:  2020-04-20       Impact factor: 5.084

4.  A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

Authors:  Lanying Du; Guangyu Zhao; Yang Yang; Hongjie Qiu; Lili Wang; Zhihua Kou; Xinrong Tao; Hong Yu; Shihui Sun; Chien-Te K Tseng; Shibo Jiang; Fang Li; Yusen Zhou
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

Review 5.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

6.  Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors:  Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

7.  Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Authors:  Abdul S Yunus; Trent P Jackson; Katherine Crisafi; Irina Burimski; Nicole R Kilgore; Dorian Zoumplis; Graham P Allaway; Carl T Wild; Karl Salzwedel
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

8.  A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.

Authors:  John V Williams; Zhifeng Chen; Gabriella Cseke; David W Wright; Christopher J Keefer; Sharon J Tollefson; Ann Hessell; Amy Podsiad; Bryan E Shepherd; Pietro Paolo Sanna; Dennis R Burton; James E Crowe; R Anthony Williamson
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

9.  Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.

Authors:  Prasad Rallabhandi; Rachel L Phillips; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Theresa L Gioannini; Jerrold P Weiss; Jesse C Chow; Lynn D Hawkins; Stefanie N Vogel; Jorge C G Blanco
Journal:  MBio       Date:  2012-08-07       Impact factor: 7.867

10.  Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.

Authors:  Gertrud U Rey; Congrong Miao; Hayat Caidi; Suvang U Trivedi; Jennifer L Harcourt; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.